New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. - Wikidata - awgldk - TriplyDB

New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.

New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.

http://www.wikidata.org/entity/Q37450688

about

In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1 HIV type 1 Gag as a target for antiviral therapy Pharmacological intervention of HIV-1 maturation Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.Protease cleavage leads to formation of mature trimer interface in HIV-1 capsid HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention Discovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid Complexes Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing Structural and functional insights into the HIV-1 maturation inhibitor binding pocket Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396 Identification of potent maturation inhibitors against HIV-1 clade C Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system.Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice.Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition.Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C HIV-1 assembly, budding, and maturation.Human Immunodeficiency Virus Gag and protease: partners in resistance.HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process HIV-1 B-subtype capsid protein: a characterization of amino acid's conservation and its significant association with integrase signatures.

P2860

Q24599377-C557568A-DAEA-4772-BB77-E56B11B492EC Q24614498-B7658205-2F38-4A2E-B803-05A82FECFB8E Q26771739-F51A29F6-5BF7-4F5D-B56C-AFC308C71333 Q27324263-780878B9-EF33-4FAD-A5E9-73EEDBF64562 Q27342743-15A4A940-58A8-4692-9142-D0247DD03924 Q27666355-341B504D-23BC-4868-B4CC-9CBB992516FB Q27678859-B1DCFC31-5EBA-47F2-95E1-9FEBBD5ABCD4 Q28480389-D1090B37-0110-4F2B-A397-AE86309962FC Q28485054-F7821BBA-B657-440D-81B2-5A2CC18368C9 Q28828191-AF31A4ED-D886-451E-A13E-9C2132656616 Q28829072-F0CE0E66-2790-475C-9763-EA5FD94E69C7 Q33957533-8BAFFACE-DCFB-4869-AAE2-D2F1267A5BE7 Q35832693-FA21346D-B438-4AF5-BB46-147139A45DD6 Q35992805-071C5EC1-E483-4BF2-8A41-68EFF43FCD9D Q37287731-3C5B596E-D785-42F9-94EF-3910C5242D1F Q37336728-130432F7-9320-4E88-9B73-7A31F86777A6 Q37676344-079BF196-4A4F-4F29-85C1-083FD2A5C72F Q38023864-90E75B96-3AA3-405B-B05F-9F6B070CF7C6 Q38032330-E083A88A-B8F5-4843-B9B1-4A7165207777 Q38549717-65A53588-A4E3-4D0C-891A-67D1C4948E4B Q41844750-4A0CF826-96D4-4063-A686-0F1CC4A2E809 Q42240376-C73AC44C-ED2B-4702-9A21-BA4BCAD03281

P2860

New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.

http://www.wikidata.org/entity/Q37450688

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

New small-molecule inhibitor c ...... irus type 1 virion maturation.

@en

New small-molecule inhibitor c ...... irus type 1 virion maturation.

@nl

type

label

New small-molecule inhibitor c ...... irus type 1 virion maturation.

@en

New small-molecule inhibitor c ...... irus type 1 virion maturation.

@nl

prefLabel

New small-molecule inhibitor c ...... irus type 1 virion maturation.

@en

New small-molecule inhibitor c ...... irus type 1 virion maturation.

@nl

P1433

Q37450688-55D2F3AD-6DB1-4B7E-8CB6-559001DAF2EE

P1476

Q37450688-BE48AA6D-7DCF-4D0D-B85C-ACAA43339757

P2093

Q37450688-09C26225-4C00-46C9-B6BB-E3213D082ED6

Q37450688-0CDD434B-107F-44C5-B04D-00A9837237AB

Q37450688-0F812C97-54C7-43D1-BAE7-49CD34DE4A88

Q37450688-28996544-EA37-44EE-A797-D9F9C73F72DC

Q37450688-317404E3-F511-4F08-B62A-C95181A21257

Q37450688-393FCD39-F3CB-4707-884A-86FC4407FF12

Q37450688-5F391D08-CE0A-453C-97E2-4B1A5943EBD7

Q37450688-69AF518D-2388-4B0C-8AC1-DDC866C21FD9

Q37450688-931D7618-F13F-4153-AD28-21F293A1827E

Q37450688-99E82D8F-7E1E-4626-91C0-AA1B935B245C

P2860

Q37450688-0E0ED02C-07CA-49FB-8C89-0995DDB5AFB6

Q37450688-15D005EF-E7C7-4E1E-9564-4DD739D9A696

Q37450688-17CBEEBD-C6A6-4760-89AE-BD9364207BB0

Q37450688-1BCF8BAC-AA71-4B50-B75C-FD91656970FF

Q37450688-48ECDF6F-56DA-479A-84FE-44056CAD7E45

Q37450688-4FD0C26C-0E4A-4D72-A7CA-2EB026044ACF

Q37450688-5442480D-4C73-4BC7-AFE6-1DD7B1C3DBAF

Q37450688-58AFA94F-A989-47A7-A68D-6A8ADC2A83CE

Q37450688-70BC17CE-1875-490E-AEE7-AA3F8D302D74

Q37450688-7FECDDD0-60E9-43D2-8863-CF7D692463AC

P304

Q37450688-6F9C4AA8-1117-4DF7-896B-90E368D000F3

P31

Q37450688-9CF1C0A1-D339-45BE-80F5-0F21FFB1F19D

P356

Q37450688-7E8F1A72-CD90-4941-9268-ED2FC5714617

P407

Q37450688-1948A7BD-649A-43CD-84AB-967193C3B038

P433

Q37450688-BB0324B6-1574-424D-BC20-E2EBC853F97E

P478

Q37450688-AB247D2A-D343-49CA-B65D-A50BAAF07C3B

P577

Q37450688-0C570410-6773-4EF1-BD9D-397BD13FBCDA

P5875

Q37450688-D52BCE5B-F138-43E5-9F5E-13BC07E70DBD

P698

Q37450688-42F92D2A-354E-4FD1-9FB9-D6D74E3C9225

P932

Q37450688-4A9E0655-3146-45BC-95A5-4D3C38FE2E25

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

New small-molecule inhibitor c ...... irus type 1 virion maturation.

@en

P2093

Amy K Patick

http://www.w3.org/2001/XMLSchema#string

Chris Pickford

http://www.w3.org/2001/XMLSchema#string

Edward Murray

http://www.w3.org/2001/XMLSchema#string

Hua Wu

http://www.w3.org/2001/XMLSchema#string

Jason Isaacson

http://www.w3.org/2001/XMLSchema#string

Joan Cao

http://www.w3.org/2001/XMLSchema#string

Juin Fok-Seang

http://www.w3.org/2001/XMLSchema#string

Manos Perros

http://www.w3.org/2001/XMLSchema#string

Paul Griffin

http://www.w3.org/2001/XMLSchema#string

Qinghai Peng

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid

Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates.

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Maturation inhibitors: a new therapeutic class targets the virus structure

Raltegravir with optimized background therapy for resistant HIV-1 infection

Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells.

High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Maraviroc for previously treated patients with R5 HIV-1 infection

P304

5080-5087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00759-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26871747

http://www.w3.org/2001/XMLSchema#string

P698

19805571

http://www.w3.org/2001/XMLSchema#string

P932

2786326

http://www.w3.org/2001/XMLSchema#string